 |
|
|
| Home -> Support -> Articles -> Brief Introduction of Recombinant AAV -> Plasmids for producing recombinant AAV2 / Myo2A | ||
| Quick Inquiry |
Plasmids for producing recombinant AAV2 / Myo2A Item No.: PKIT-243241Shipping: 2 μg Storage: -20°C INTRODUCTION AAV serotype Myo2A is an engineered RGD-containing AAV capsid variant which is derived from AAV9 capsid through directed evolution in mice and primates. AAV Myo2A serotype has the tropism for muscle cell transduction. It is dependent on integrin heterodimers for transducing mouse and human cells. Systemic administration of AAV Myo2A at low dose can achieve therapeutic efficacy in disease models. Compared to those native AAV capsids in mouse models of genetic muscle disease, AAV Myo2A shows enhanced potency and therapeutic efficacy. RGBiotech offers a packaging plasmid kit that can be used for producing AAV2 / Myo2A viral particles. This kit contains all plasmid vectors that is required for AAV2 / Myo2A production including the empty/GFP control transfer plasmid vector, the helper plasmid vector, and the rep/cap plasmid vector. We can also synthesize and clone your target gene (GOI) into the empty AAV transfer / cis / expression plasmid vector. Please contact us at admin@rgbioech.com for more information and quotation. KIT COMPONENTS 1) AAV transfer / cis / expression plasmid vector [Empty]2) AAV transfer / cis / expression plasmid vector [GFP control] 3) AAV transfer / cis / expression plasmid vector [GOI] 4) AAV helper packaging plasmid vector 5) AAV rep / cap packaging plasmid vector RELATED PRODUCTS AAV PlasmidsREFERENCES [1] Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, Krunnfusz A, Tavakoli S, Widrick JJ, Messemer KA, Troiano EC, Moghadaszadeh B, Peacker BL, Leacock KA, Horwitz N, Beggs AH, Wagers AJ, Sabeti PC. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021 Sep 16;184(19):4919-4938.e22.[2] Lebek S, Caravia XM, Straub LG, Alzhanov D, Tan W, Li H, McAnally JR, Chen K, Xu L, Scherer PE, Liu N, Bassel-Duby R, Olson EN. CRISPR-Cas9 base editing of pathogenic CaMKIIδ improves cardiac function in a humanized mouse model. J Clin Invest. 2024 Jan 2;134(1):e175164. |
|
|
Products & Services Resources | ||
|
Home Products & Services Support About Us Contact Us |
Promotions Flyers Brochures Publications News & Events |
Terms & Conditions Privacy Disclaimers |
Contact Us EMAIL: admin@rgbiotech.com |
||
| © RGBiotech All Rights Reserved. | |||||